Camilla Turetta, Roberta Mazzeo, Giuseppe Capalbo, Salvatora Miano, Robert Fruscio, Violante Di Donato, Francesca Falcone, Giorgia Mangili, Sandro Pignata, Innocenza Palaia
Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin's gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in a previous systematic review were not duplicated. In total, details of 367 patients were collected, as follows: histological features, clinical presentation, treatment, recurrent rate, treatment of recurrence and outcome...
November 13, 2023: Tumori
Francesca Valent, Giulia Degani, Monica Gri, Raffaela Donato, Giulia Varadi, Giovanni Gerardo Cardellino, Gianpiero Fasola
No abstract text is available yet for this article.
October 30, 2023: Tumori
Andrea Olsen, Alexandra Lebedeva, Polina Nosova, Vladislav Nikulin, Margarita Sharova, Ekaterina Ignatova, Vladislav Mileyko, Maxim Ivanov
INTRODUCTION: Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort. METHODS: We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular profiling data from patients receiving immune checkpoint inhibitors)...
October 11, 2023: Tumori
Andrea Luciani, Antonio Ghidini, Karen Borgonovo, Maria Chiara Parati, Fausto Petrelli
Patients whose tumours harbour epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) driver mutations can benefit most from treatment with tyrosine kinase inhibitors (TKIs). Most trials with immune checkpoint inhibitors (ICIs) included few patients whose tumour had oncogenic driver alterations. We therefore performed a meta-analysis of studies reporting the activity of ICIs in oncogene addicted NSCLC. A comprehensive search of MEDLINE, The Cochrane Library and EMBASE was conducted to identify relevant studies published up to 31 January 2021...
October 2023: Tumori
Ugo Testa, Germana Castelli, Elvira Pelosi
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK -fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK -rearranged LUADs when used as first- or second-line agents...
September 29, 2023: Tumori
Bruna Cerbelli, Alessio Cirillo, Giulia Pomati, Angelina Pernazza, Andrea Ascione, Simona Pisegna, Annalinda Pisano, Martina Leopizzi, Maria Gemma Pignataro, Leopoldo Costarelli, Antonino Mulè, Andrea Vecchione, Piera Catalano, Luigi Coppola, Giuseppe Perrone, Letizia Perracchio, Lucia Anemona, Antonio Mastracchio, Stefano Nardi, Renato Reitano, Annalisa Massari, Lucia Rosalba Grillo, Fabrizio Liberati, Carlo Della Rocca, Paolo Marchetti, Andrea Botticelli, Giulia D'Amati
BACKGROUND: Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period. METHODS: The survey comprised 12 questions regarding the availability of SP142 in the pathology departments, the percentage of positive tests, the difficulties of pathologists in cases close to cut-off value and the tested samples...
September 19, 2023: Tumori
Clorinda Brignola, Sara Volorio, Giovanna De Vecchi, Daniela Zaffaroni, Valentina Dall'Olio, Frederique Mariette, Domenico Sardella, Fabio Capra, Stefano Signoroni, Emanuele Rausa, Marco Vitellaro, Valeria Pensotti, Maria Teresa Ricci
Lynch Syndrome is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants or epimutation in one of the DNA mismatch repair genes. De novo pathogenic variants in mismatch repair genes have been described as a rare event in Lynch Syndrome (1-5%), although the prevalence of de novo pathogenic variants in Lynch Syndrome is probably underestimated. The de novo pathogenic variant was identified in a 26-year-old woman diagnosed with an adenocarcinoma of the caecum with mismatch repair protein deficiency at immunohistochemistry and a synchronous neuroendocrine tumor of the appendix with normal expression of mismatch repair proteins...
September 11, 2023: Tumori
Maria Cristina Leonardi, Matteo Pepa, Mattia Zaffaroni, Maria Giulia Vincini, Rosa Luraschi, Sabrina Vigorito, Anna Morra, Samantha Dicuonzo, Giovanni Carlo Mazzola, Marianna Alessandra Gerardi, Maria Alessia Zerella, Domenico Cante, Edoardo Petrucci, Giuseppina Borzì, Maristella Marrocco, Matteo Chieregato, Luciano Iadanza, Francesca Lobefalo, Marco Valenti, Anna Cavallo, Serenella Russo, Marika Guernieri, Tiziana Malatesta, Ilaria Meaglia, Marco Liotta, Isabella Palumbo, Marta Marcantonini, Emilio Mezzenga, Sara Falivene, Cecilia Arrichiello, Maria Paola Barbero, Giovanni Battista Ivaldi, Gianpiero Catalano, Cristiana Vidali, Caterina Giannitto, Antonella Ciabattoni, Icro Meattini, Cynthia Aristei, Roberto Orecchia, Federica Cattani, Barbara Alicja Jereczek-Fossa
This study quantified the incidental dose to the first axillary level (L1) in locoregional treatment plan for breast cancer. Eighteen radiotherapy centres contoured L1-L4 on three different patients (P1,2,3), created the L2-L4 planning target volume (single centre planning target volume, SC-PTV) and elaborated a locoregional treatment plan. The L2-L4 gold standard clinical target volume (CTV) along with the gold standard L1 contour (GS-L1) were created by an expert consensus. The SC-PTV was then replaced by the GS-PTV and the incidental dose to GS-L1 was measured...
September 9, 2023: Tumori
Dario Trapani, Fabio Girardi, Saverio Cinieri, Giuseppe Curigliano
Improved strategies of cancer prevention and control have resulted in tangible benefits for patients with cancer. Disparities in outcome have been reported as a result of inequal access to health care. Historically, differences in health outcomes at population level have been reported according to key characteristics, including race, ethnicity and, more recently, ancestry. These population descriptors have been used to display the differences in the outcome and highlight actionable areas of health disparities, through policy and population health interventions...
September 9, 2023: Tumori
Laura Sala, Chiara Maura Ciniselli, Fabio Bozzi, Valeria Summo, Chiara Bonini, Silvia Brich, Alessia Bertolotti, Trupia Desiré Viola, Chiara Costanza Volpi, Sara Pizzamiglio, Biagio Paolini, Antonella Aiello, Giovanni Apolone, Paolo Verderio, Umberto Cortinovis
INTRODUCTION: The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions coupled with the micro-textured devices, that have been recently introduced after the recall of macro-textured ones, is still lacking...
August 14, 2023: Tumori
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
BACKGROUND: Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022, focusing on the perception of the problem by oncologists. MATERIALS AND METHODS: An anonymous 31-item online questionnaire was shared on 15 September 2022 on the AIOM website...
August 10, 2023: Tumori
Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao
OBJECTIVE: The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis. MATERIALS AND METHODS: A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis...
August 9, 2023: Tumori
Celeste Cagnazzo, Bruno Ficara, Federica Palermo, Franca Fagioli
The consequences of the Italian privacy legislation, that represents a very restrictive implementation of the general European regulation on data protection, have mainly been felt at the level of observational research. In this field is not always possible to obtain the consent of subjects, and as for retrospective studies, it is not currently clear which is the correct regulatory procedure to follow. This uncertainty in the law's implementation has given way to multiple interpretations, making it difficult to obtain a homogeneous path in Italy...
August 7, 2023: Tumori
Kamala Dhakal, Panpan Wang, Joanes Faustine Mboineki, Mikiyas Amare Getu, Changying Chen, Daya Laxmi Shrestha
INTRODUCTION: Patients with cervical cancer report experiencing physical, psychological, economic, and social problems daily. An exploration of supportive care needs is important for patients and their families to cope with diagnosis, treatment, recovery or even death. OBJECTIVE: This study explores the perceived supportive care needs of Nepali patients with cervical cancer who are undergoing cancer treatment. METHODS: A descriptive qualitative research design was utilized with semi-structured interviews to probe patients with cervical cancer's supportive care needs...
August 2023: Tumori
(no author information available yet)
No abstract text is available yet for this article.
August 2023: Tumori
Fausto Petrelli, Agostina De Stefani, Ivano Vavassori, Federica Motta, Andrea Luciani, Francesca Trevisan
OBJECTIVE: To evaluate various outcomes of different lengths of androgen deprivation therapy in high- and very-high-risk prostate cancer, we conducted a network meta-analysis of randomized trials. The treatment of high-risk PC comprises the use of radical radiotherapy associated with various durations of androgen deprivation therapy, with luteinizing hormone releasing hormone analogues initiated during or immediately before the beginning of radiation. METHODS AND MATERIALS: This study followed the PRISMA extension statement to report network meta-analyses...
August 2023: Tumori
Ida Taglialatela, Luigi Mariani, Katia Fiorella Dotti, Laura Di Vico, Maria Neve Pisanu, Claudia Facchinetti, Filippo De Braud, Laura Anna Maria Ferrari
BACKGROUND: Insertions of central venous catheters (CVC) has become a common practice in Onco-Hematologic Units to administer systemic treatments. Unfortunately they can cause complications influencing patient's care-pathway significantly. Oncological patients have a higher thrombotic risk than the general population, therefore specific recent risk scores are spreading through the clinical practice, such as Khorana, Protecht, COMPASS-CAT, and Michigan scores. METHODS: A retrospective cohort of 177 out of a total of 3046 outpatients accessing the Medical Day Hospital of Istituto Nazionale Tumori di Milano from March 2019 to February 2021 aged ⩾ 18 years who developed CVC complications was analyzed extracting clinical data from their medical records...
August 2023: Tumori
Michele Dionese, Francesco Pierantoni, Elisabetta Bezzon, Enrico Cumerlato, Davide Bimbatti, Umberto Basso, Marco Maruzzo, Vittorina Zagonel
INTRODUCTION: Evaluation of tumor response according only to dimensional criteria may underestimate treatment benefit in patients treated for metastatic renal cell carcinoma (RCC). In this study we evaluated the role of lesion enhancement modifications and Choi criteria in patients affected by renal cell carcinoma treated with immunotherapy. METHODS: We collected data of 60 consecutive patients (with a total of 154 measurable lesions) treated with immunotherapy (nivolumab or ipilimumab plus nivolumab) at a single Institution...
July 28, 2023: Tumori
Ivana Bozovic Spasojevic, Andrea Ferrari, Johan De Munter, Ashley Gamble, Assia Konsoulova-Kirova, Katie Rizvi, Carina Schneider, Marie Balsat, Anna Castleton, Leila Gofti-Laroche, Anita Kienesberger, Beate Timmermann, Josef Vormoor, Emmanouil Saloustros, Daniel P Stark
BACKGROUND: It is well documented that traditional health care models do not meet the specific needs of Adolescents and Young Adults (AYA) cancer patients. METHODS: We explore a map of the development of age-specific AYA cancer care across Europe, from the perspective of healthcare professionals with an interest in AYA care, in order to understand the specific challenges and map progress over time. An on-line survey was developed by international professional cancer organisations...
July 24, 2023: Tumori
Monica Terenziani, Alberto Eugenio Tozzi, Laura Diaco, Eleonora Biasin, Alessandro Cattoni, Ileana Croci, Donatella Fraschini, Giovanna Giorgiani, Riccardo Haupt, Monica Muraca, Marta Pillon, Giovanna Sironi, Maria Grazia Valsecchi, Angela Mastronuzzi
INTRODUCTION: Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services in Italy, investigate strengths and weaknesses, analyze improvements of awareness in the field, and identify the gaps that need to be addressed by different centers...
July 12, 2023: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.